Cognitive impairment associated with antiepileptic drug (AED) therapy in children is an important concern given the potential negative effects of treatment on school learning and performance. Unfortunately, there have been few studies examining the cognitive effects of AEDs in this population and no adequate studies of newer AEDs. This article will discuss the effects of the traditional and newer AEDs on neuropsychological function in children. Because of various limitations in the designs of these studies, however, many of the studies report inconclusive findings. Although it will be necessary to overcome many programmatic and procedural hurdles, well-designed randomized prospective studies that are of adequate length to determine how AEDs ultimately relate to school performance and social adjustment are needed to firmly establish the cognitive and behavioral effects of AEDs in children.
NEUROLOGY 2004; 62:872-877 Cognitive side effects of antiepileptic drug (AED) therapy in adults generally are well established for medications that were introduced before the 1990s, with the greatest cognitive impairment risk associated with phenobarbital (PB) and traditional benzodiazepines (BZDs). 1 For other AEDs, the cognitive profiles generally are comparable, with modest motor and psychomotor slowing and no consistent cognitive difference among carbamazepine (CBZ), phenytoin (PHT), or valproate (VPA). 1 Many AEDs introduced during the 1990s (e.g., gabapentin [GBP], lamotrigine [LTG] , levetiracetam [LEV] and tiagabine [TGB] ) are thought to have fewer cognitive side effects. 1 In contrast, the cognitive side effects of topiramate (TPM) are slightly greater than those of VPA in adjunctive therapy but can be notably greater in some patients, especially if TPM is initiated quickly and given at higher doses. 1 Formal neuropsychological data are inadequate or nonexistent for the other new AEDs.
Studies in rats have demonstrated potentially serious AED effects in the developing brain, including apoptotic neurodegeneration. 2, 3 In humans, relatively few studies examining the AED effects in children have been performed, although the American Academy of Pediatrics and the American Academy of Neurology have highlighted the need for prospective, properly controlled studies to establish cognitive and behavioral outcomes. 4, 5 Even modest cognitive AED side effects in children may have significant cumulative consequences if they restrict the rate at which academic skills are initially learned and subsequently mastered.
Unfortunately, most pediatric AED studies of cognitive side effects have used global IQ as the primary dependent measure, which tends not to be sensitive to subtle or more modest neuropsychological change. Other studies examining general AED effects have combined various AEDs with different cognitive risks into a single group. 6 In addition, design limitations, including retrospective review, comparison of AED groups without random assignment, absence of appropriate controls, and small sample sizes, often have led to inconclusive or conflicting results. Even a study design in which seizure-free patients are tapered off medication, which avoids many methodologic confounds, 7 may have limited generalizability to other populations because children with more difficult to control epilepsy are more likely to display IQ declines over time. 8 Because potential cognitive AED side effects in children is an important area of inquiry, albeit an extremely difficult one to study because of methodologic and procedural reasons, we summarize our current knowledge in this area and highlight many of the design limitations that need to be addressed in future prospective studies.
A careful reading of one of the first comprehensive longitudinal studies using formal psychological testing illustrates many of the difficulties of conducting AED studies in children. 9 Children with newly diagnosed epilepsy (n ϭ 72) aged between 1.5 and 16 years underwent psychometric evaluations within 2 weeks of initial diagnosis and then on a yearly basis for an average of 4 years. In addition, 45 patients had siblings who served as nonlongitudinal control subjects and who were tested only once at the beginning of the study.
No IQ difference was seen between the 45 children with epilepsy and their siblings (98.0 Ϯ 19.8 vs 104.4 Ϯ 20.3; p ϭ 0.13). In the entire group of 72 children with epilepsy (i.e., with and without sibling control subjects), the IQ increased from 99.7 Ϯ 20.2 at baseline to 101.0 Ϯ 20.5 after 4 years of treatment with a variety of different monotherapy and polytherapy AED combinations. However, 8 of 72 children (11%) had an IQ decline of at least 10 points; the children at greatest risk for IQ decline had above-average IQs at baseline. These children also had an earlier age of seizure onset, with seizures that were more difficult to control.
There are several areas in which significant method variance may have contributed to the observed findings. More than half of the children with epilepsy had been prescribed AEDs before their initial assessment. Thus, acute AED effects may have depressed initial IQ scores and thereby decreased the likelihood of detecting any long-term AED effect. It also is possible that IQ declines associated with early seizure onset were related to negative effects on motor skills rather than on more traditional "cognitive" factors. The IQ change in the eight children with 10ϩ IQ point declines may simply have reflected the expected test-retest instability associated with IQ testing in young children. At age 9 years, for example, 15% of children given an IQ test would be expected to display a change of at least 15 points when tested 2 years later. 10 Another possibility is that because the children were tested yearly, practice effects from repeated evaluations may have offset performance decline. 11, 12 Because the sibling control group was tested only once, longitudinal control data were not available for comparison. Finally, although IQ is a well-established measure, it does not reflect a broad spectrum of cognitive and behavioral functions, and more subtle neuropsychological effects may have been missed. Thus, despite the many strengths of this study (e.g., prospective enrollment and psychometric assessment), its limitations do not allow any firm conclusion about AED effects on children's cognitive abilities to be made.
Older AEDs. Phenobarbital. Children taking PB for seizure prophylaxis after a febrile seizure tend to have lower IQs or display IQ declines compared with control subjects, 13, 14 although this difference does not always reach significance. 15 The effect of PB on IQ decreases after drug withdrawal, 13, 14, 16 and its negative effect on P300 latency (an electrophysiologic measure of cognitive processing speed) appears reversible after drug discontinuation. 17 Nevertheless, there may be lingering effects on academic achievement, even when tested 3 to 5 years later. 16 These longer-term effects suggest that many children do not fully catch up and compensate for "lost time" associated with decreased cognitive processing during PB therapy. Similar IQ effects have been described for children treated with PB for epilepsy (table) . PB may decrease fine motor performance, although this effect may habituate. 18 Because of the effects of PB on attention, 19 measures such as performance IQ, in which there is a prominent timed component, often are decreased. 8, 20 The negative effects of PB on cognition are greater than those of VPA 21, 22 or CBZ. 23 These effects sometimes show up only as the absence of an expected practice effect with repeated assessment, an effect which is still present at least in part with CBZ and VPA. 22, 24 In summary, PB may decrease IQ, although this results in part from decreased processing efficiency and poorer attention. Declines in IQ are thought to reflect slowed mental growth rather than loss of previously acquired cognitive function or cognitive regression, and the declines in speeded performance are largely reversible. However, the longer-term effects of PB on academic achievement suggest that many children never fully catch up after PB discontinuation.
Carbamazepine. The few studies of CBZ effects on IQ in children, which report no significant effects, are limited by small sample sizes and the absence of control groups (see table) . 25, 26 CBZ effects on motor speed have been inconsistent, even in the same sample. 27 A beneficial effect of CBZ on reaction time has been reported in children treated clinically, although it is unclear whether this effect was a result of improved seizure control. 28 Poorer performance for memory and speed has been associated with CBZ in children with benign rolandic epilepsy, and some patients appear to be particularly susceptible to CBZ, developing disproportionate cognitive side effects across many tasks, such as memory recall and visual search. 29 In one study, CBZ affected memory more than VPA, but the magnitude of this effect is comparable with that of PHT. 30 The differential effects of CBZ compared with VPA on academic achievement measures are inconsistent. 31 In summary, CBZ does not appear to affect global IQ. There appears to be a modest negative CBZ effect on children's memory, although it unclear if this results in any reduction in academic achievement.
Phenytoin. For children attending regular schools, PHT has been associated with poorer reading compared with barbiturates, ethosuximide, or other AEDs, although drugs were not randomly assigned. 32 The risk for cognitive decline in children who received treatment with PHT has been postulated to be related to serum folate levels, but this remains unproven. 33 In summary, although no direct comparisons of PHT with other AEDs in children have been performed, PHT appears to have a smaller effect on IQ than does PB based on the improvement observed after changing AEDs. 34 The effects of PHT on memory appear similar to those of CBZ. 30 The effects of PHT on academic achievement are unknown.
Valproate. In one small study of children, VPA had fewer negative effects on memory than CBZ or PHT. 30 As with most AEDs, there is a dosedependent relationship on cognitive functions, with higher VPA doses associated with lower neuropsychological performance on a variety of non-IQ measures, including mazes, auditory-visual integration, and seat movement (a measure of child activity). 35 The beneficial psychotropic effects of VPA on mood are well established in adults, and VPA appears effective in treating disruptive children with explosive temper and mood lability. 36 In summary, although one study suggests fewer adverse cognitive effects with VPA compared with CBZ or PHT, this effect has not been observed in other reports. 17, 24 The effect of VPA on IQ, memory, and academic achievement has not been studied adequately, 30, 31 although the effect appears less severe than with PB. 21 Newer AEDs. With the exception of clobazam (CLB), a novel BZD that has not been approved in the United States, there are virtually no formal neuropsychological investigations of the recently introduced AEDs in children. Consequently, what we describe is based mainly on side effects reported in various clinical trials, acknowledging that these data are coarse substitutes for formal neuropsychological results.
Clobazam. Children randomized to CLB or traditional AED (CBZ or PHT) do not have neuropsychologically distinct profiles when tested at either 6 weeks or 12 months after drug initiation. 37 However, performance on several measures (e.g., performance IQ and memory) was correlated with CLB serum concentration. Despite the absence of group differences for direct group comparisons, significant practice effects were present on many tests for children receiving traditional AED therapy (n ϭ 14) when tested 1 year later (e.g., full-scale IQ, performance IQ, memory, and digit span); no similar practice effect was seen in the children taking CBZ (n ϭ 10). Thus, significant group differences would appear likely with a larger group of patients completing the 1-year study.
Felbamate. Felbamate (FBM) was the first of the newer AEDs to be introduced into the US market, but the development of idiosyncratic aplastic anemia and hepatotoxicity has markedly limited its use. In a report of adjunctive FBM use in adults and children, including 80 children with Lennox-Gastaut syn-drome, the most common treatment-emergent side effect was drowsiness in 13% of the sample, 38 a figure slightly less than the 16% reported previously in a sample of patients with Lennox-Gastaut syndrome. 39 Gabapentin. Children taking GBP are at risk for behavioral changes, including hyperactivity, irritability, agitation, and aggression, even in the presence of improved seizure control. 40 Mentally retarded children appear at greater risk for developing aggressive behavior with GBP. 41 The behaviors reported as most worrisome include tantrums, directed aggression, hyperactivity, and defiance. 42 These changes are reversible by either dose reduction or drug discontinuation.
Lamotrigine. Aggressive behavior has been associated with LTG, particularly in children with lower levels of intellectual function. 43 In a multicenter sample of 285 children, behavioral side effects of LTG were seen in 2.5% of the sample. 44 In a doubleblind adjunctive trial primarily of children with Lennox-Gastaut syndrome, significant behavioral improvement and increased alertness were noted in 17 of 17 patient responders (Ն50% reduction in seizure frequency) during the open phase, with 4 of 10 nonresponders developing agitation. 45 Behavioral improvement may be seen in the absence of concomitant seizure reduction, which may be related in part to decreased interictal epileptiform activity on EEG. 46 In children with tuberous sclerosis who were treated with LTG (46% monotherapy), improvement in behavior or alertness was seen in 32% of the subjects. 47 Parents rated the children as improved, with a longer attention span and improved alertness in slightly Ͼ50% of a sample of children with epilepsy after beginning LTG therapy. 48 Even children characterized as autistic reportedly were improved. Positive effects were observed in children without improved seizure control, again suggesting a positive psychotropic effect independent of seizure efficacy. In summary, some children may develop irritability and aggression, although behavioral improvement may be noted in others, which may be related to EEG normalization and improved seizure control.
Levetiracetam.
Only a few open-label studies in children have been completed. In a small sample of 24 children given levetiracetam (LEV) as adjunctive therapy, somnolence was reported in 6 children, nervousness in 5, and emotional lability in 3. 49 Similar side effects were reported in a different study, with behavioral effects present in 15 of 39 patients (aggression in 6 patients, sedation in 6, hyperactivity in 4, and other behavioral events in 9). 50 More importantly, however, 10 of 39 children reported improvements, including cognition and concentration in 5, increased alertness in 5, and improved behavior in 2. These improvements occurred in several patients without improved seizure control.
In an open-label study in patients with autism, LEV had beneficial effects on attention, hyperactivity, and mood instability. 51 A decrease in aggressive behavior was noted in a subsample, although a sig-nificant increase in aggressive behavior was observed in children who recently had been withdrawn from antiaggression medication (e.g., risperidone).
Oxcarbazepine. No change in IQ scores was associated with oxcarbazepine (OXC) in one small openlabel monotherapy trial, but the small sample size, insensitive cognitive measures, and lack of blinding, randomization, or control groups are critical limitations of the study. 52 In a larger randomized, placebocontrolled study of children receiving OXC adjunctive therapy, somnolence was reported in 35% of children receiving OXC vs 14% of control subjects. 53 In a comparative monotherapy study of OXC and PHT, somnolence was reported in 25% of patients receiving OXC and in 30% of patients receiving PHT. 54 Apathy was found in 12% of children treated with OXC and in 11% treated with PHT. The largest differential effect was for nervousness, with 2% of OXC-treated children reporting this finding vs 12% of PHT-treated children.
Tiagabine. In an adjunctive trial of children at least 2 years of age, 19% reported asthenia, 10% nervousness, and 17% somnolence. 55 Topiramate. In a double-blind, randomized, placebo-controlled TPM add-on trial of 86 children with partial seizures who were evaluated after 16 weeks, children receiving TPM had greater emotional lability (12% vs 4%), fatigue (15% vs 7%), difficulty with attention and concentration (12% vs 2%), and forgetfulness and impaired memory (7% vs 0%). 56 However, no children taking TPM discontinued the study because of treatment-emergent adverse effects. These findings were observed despite significantly improved seizure control with TPM.
In a report of clinical experience with TPM, either as monotherapy or adjunctive treatment in 49 children ranging in age from 1.5 to 19 years, adverse effects included decreased cognition in 11, decreased speech in 8, decreased energy in 7, and worsened behavior in 7, with 25 patients showing problems in at least one of these areas. 57 Interestingly, increased alertness was described in eight patients, and improved behavior was seen in four patients. Half of this sample with partial seizures experienced a Ͼ50% reduction in seizure frequency, although poorer results were obtained in patients with generalized seizures.
Vigabatrin. Although available throughout much of the world, vigabatrin (VGB) has not been approved for use in the United States because of risk of visual field constriction. VGB is an effective agent for management of infantile spasms, particularly those originating from tuberous sclerosis. 58 In the context of intractable seizures in infantile spasms, however, the favorable therapeutic effects of VGB continue to make it a medication that may be considered first-line therapy. 59, 60 VGB has been associated with acute encephalopathy in a 6-month-old child with West syndrome, 61 and acute reversible psychosis also has been described. 62 In an open-label, randomized comparison of VGB with CBZ, 1 of 38 children taking VGB developed antisocial behavior, and 6 patients displayed irritability and excitability; excessive sedation was described in 6 of 32 children taking CBZ. 63 Zonisamide. A higher risk of psychiatric side effects, including psychotic episodes, appears to be present in children treated with zonisamide (ZNS). These side effects can occur years after treatment is started and appear in children who are cognitively intact. 64, 65 Obsessive-compulsive symptoms in children may be related to psychotic episodes. These behavior changes can occur with normal blood levels and in children in whom ZNS has provided good seizure control.
Conclusions.
Children with epilepsy are at increased risk for cognitive impairment and difficulties in learning that may affect school performance, and at least some component may be attributed to longterm AED therapy. The evidence is fairly strong to indicate the negative effect of PB on IQ, with the greatest effect seen on measures with a timed component. Although this IQ effect decreases over time after drug withdrawal, there appears to be a longerterm negative effect on academic achievement in which it is unclear whether the children ever "catch up" in terms of performance.
The relative effects of other AEDs in children are largely unknown. Even the magnitude of AED effects is difficult to determine because the majority of studies are either open label, have inadequate sample sizes, lack random assignment, or fail to include appropriate controls. In addition to these methodologic limitations, the duration of these studies is insufficient to determine long-term cumulative effects of AED treatment. Further, there are no studies of the more recently introduced AEDs in children using formal neuropsychological assessment. Thus, there is a critical need for appropriately designed prospective studies to properly delineate the effects of AEDs in children, not only on general intellectual function but also on general neuropsychological variables, such as attention, memory, psychomotor speed, behavioral functions, and academic achievement. Thus, in addition to the standard design issues of blinding, random assignment, prospective enrollment, and test selection, it is important for the studies to be of adequate duration to determine how AEDs ultimately relate to school performance and social adjustment when long-term treatment during the school years is necessary.
